CAMBRIDGE, Mass.--(EON: Enhanced Online News)--Mersana Therapeutics, Inc., today announced that Anna Protopapas, President and Chief Executive Officer, will present a company overview at the 35th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Tuesday, January 10, 2017, at 2:30 p.m. PT.
About Mersana Therapeutics
Mersana Therapeutics is a biotechnology company with highly differentiated and proprietary immunoconjugate platforms that allow for significantly higher drug loads, providing greater efficacy while simultaneously increasing tolerability. As a result, our platforms provide for expanded opportunities to provide meaningful clinical benefit to patients. Our lead program, XMT1522, is in Phase I clinical trials. Our second program, XMT1536, will be entering clinical trials in the latter part of 2017. In addition, our partners are advancing their pipeline of immunoconjugates using our platforms.